Head-to-head evidence
etrasimod vs ozanimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
etrasimod · Velsipity
Marketed by Pfizer
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · ozanimod's landscape